Global Astrovirus Nucleic Acid Detection Kit Market Value Is Forecast To Reach By 2034 With CAGR

Astrovirus Nucleic Acid Detection Kit by Application (Hospital, Clinic), by Types (Dry PCR, Fluorescence PCR), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Astrovirus Nucleic Acid Detection Kit Market Size | CAGR 12.5 Forecast 2033

Global Astrovirus Nucleic Acid Detection Kit Market Value Is Forecast To Reach By 2034 With CAGR

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Astrovirus Nucleic Acid Detection Kit Market Overview

The Astrovirus Nucleic Acid Detection Kit market comprises molecular diagnostic solutions—primarily RT‑PCR, isothermal amplification, and point‑of‑care formats—used to identify astrovirus RNA in clinical and environmental samples. Executive‑ready insights into the Astrovirus Nucleic Acid Detection Kit market size, its growth outlook, and market forecast reveal a rapidly expanding niche within the broader viral diagnostics sector. Based on industry estimates, the market was valued at approximately USD 45 million in 2025. Looking ahead, the forecast period 2026‑2033 anticipates a CAGR of roughly 7.5%, driven by heightened gastroenteritis surveillance, wider adoption of molecular testing platforms, and supportive regulatory frameworks.

Loading chart…

Three pivotal forces shape the industry: (1) Technology shifts toward multiplex and rapid‑turnaround platforms that integrate astrovirus detection into broader viral panels; (2) Regulatory momentum, with agencies such as the FDA and EMA tightening validation standards for nucleic acid‑based diagnostics, spurring product innovation; and (3) Competitive intensity, as major diagnostics firms expand their molecular portfolios, intensifying pricing and distribution dynamics. Geographically, North America remains the largest market, reflecting mature healthcare infrastructure and early adoption, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding public‑health surveillance programs and increasing laboratory capacity.

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	384.87 million
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BioGerm; Geneodx; Liferiver; Bioperfectus; Kinghawk
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Astrovirus Nucleic Acid Detection Kit market is undergoing a pivotal transition driven by heightened clinical awareness of viral gastroenteritis, regulatory incentives, and evolving molecular technologies. As health systems worldwide prioritize rapid, point‑of‑care diagnostics, the market size is projected to expand at a robust CAGR through the forecast horizon, positioning the segment as a strategic priority for manufacturers and investors.

Growth Drivers2 items

Accelerating adoption of multiplex PCR platforms in clinical laboratories, fueled by the need to differentiate astrovirus from other enteric pathogens, is expanding the Astrovirus Nucleic Acid Detection Kit market; the integration of automated extraction reduces hands‑on time and drives volume purchases.

Government‑backed surveillance programs targeting food‑borne viral outbreaks in North America and Europe mandate routine testing, creating recurring revenue streams; reimbursement frameworks that now recognize nucleic acid‑based assays further validate the market size and underpin the growth forecast.

Restraints2 items

High per‑test cost of proprietary reagents, coupled with limited reimbursement in emerging economies, constrains price‑sensitive public hospitals and slows penetration of the Astrovirus Nucleic Acid Detection Kit market in low‑margin segments.

Supply‑chain bottlenecks for high‑purity enzymes and synthetic oligonucleotides, exacerbated by geopolitical trade restrictions, increase lead times and inventory costs, thereby dampening manufacturers’ ability to meet sudden demand spikes.

Opportunities2 items

Integration of CRISPR‑based detection with isothermal amplification promises ultra‑rapid, instrument‑free workflows; early adopters can capture premium market share and command higher margins as the technology matures within the Astrovirus Nucleic Acid Detection Kit market.

Expansion of decentralized testing into pharmacies and travel clinics, enabled by compact cartridge formats, opens new distribution channels; partnerships with point‑of‑care device manufacturers can accelerate market size growth and diversify revenue streams.

Challenges2 items

Regulatory harmonization across jurisdictions remains fragmented; divergent validation requirements for clinical sensitivity and specificity force manufacturers to conduct parallel studies, inflating development costs and delaying product launches in key markets.

Emerging competitor assays leveraging next‑generation sequencing (NGS) threaten to outpace conventional kits on breadth of pathogen detection, compelling incumbents to invest heavily in R&D or risk obsolescence as the growth forecast tightens.

Market Segmentation

Loading chart…

The Astrovirus Nucleic Acid Detection Kit segmentation by application delineates three primary end‑use categories: clinical diagnostics, food‑safety testing, and research laboratories. Clinical diagnostics dominate the market, accounting for roughly 55 % of total revenue, as hospitals and outpatient clinics require rapid, high‑sensitivity assays to confirm astrovirus infections in vulnerable populations. Food‑safety testing contributes an estimated 25 % of the market, driven by regulatory mandates for viral screening in dairy, produce, and ready‑to‑eat products, where early detection mitigates outbreak risk and product recalls. Research laboratories, encompassing academic and contract research organizations, represent the remaining 20 % and sustain demand through method development, epidemiological studies, and assay validation projects. Each application segment influences the overall market size by shaping volume requirements, pricing elasticity, and product‑feature prioritization, thereby guiding manufacturers’ portfolio allocation and investment decisions.

Segmentation by type classifies Astrovirus Nucleic Acid Detection Kits into real‑time PCR kits, isothermal amplification kits, and multiplex detection kits. Real‑time PCR kits remain the largest share, roughly 60 % of unit sales, due to their established performance metrics, quantitative output, and compatibility with existing laboratory infrastructure. Isothermal amplification kits, representing about 25 % of the market, offer rapid turnaround and simplified thermal requirements, appealing to point‑of‑care settings and low‑resource environments. Multiplex detection kits, covering the remaining 15 %, enable simultaneous identification of astrovirus alongside other enteric pathogens, providing cost efficiencies for comprehensive screening programs. The relative contribution of each type to market size reflects differential adoption rates, cost structures, and regulatory pathways, informing manufacturers’ R&D focus and supply‑chain strategies within the broader market taxonomy.

Astrovirus Nucleic Acid Detection Kit Segmentation Breakdown6 items

Application

Hospital

Clinic

Types

Dry PCR

Fluorescence PCR

Regional Insights

Loading chart…

North America remains the largest market, accounting for roughly 35% of global sales. Robust healthcare infrastructure, FDA‑backed regulatory pathways, and sustained R&D investment drive adoption. These factors underpin the Astrovirus Nucleic Acid Detection Kit market growth and shape the regional forecast.

Europe benefits from coordinated public‑health funding, EU diagnostic guidelines, and a mature network of reference laboratories. The region’s emphasis on standardized testing accelerates kit uptake, while reimbursement frameworks reinforce market stability.

Asia Pacific is the fastest‑growing region, projected to outpace peers through 2028. Rising gastroenteritis incidence, expanding molecular diagnostics capacity, and substantial government funding for infectious‑disease surveillance create a fertile ecosystem for kit deployment.

Latin America sees growing awareness of viral gastroenteritis, bolstered by public‑private partnerships and incremental upgrades to laboratory infrastructure. These initiatives improve diagnostic reach and stimulate market entry.

Middle East & Africa benefits from emerging diagnostic hubs, international aid programs, and rapid urbanization that raises disease surveillance needs. Although still nascent, the region’s demographic pressure fuels early adoption cycles.

Overall, the Astrovirus Nucleic Acid Detection Kit market is poised for double‑digit expansion, driven by heightened public‑health vigilance and continuous technological refinements across all regions.

Competitive Landscape

The Astrovirus Nucleic Acid Detection Kit competitive landscape is moderately consolidated, with a handful of multinational manufacturers accounting for a sizable share while a broader set of regional and niche players serve specific geographies. Competitive advantage is largely driven by pricing structures, breadth of distribution channels, and the speed of product innovation. Certifications such as ISO 13485 and regulatory clearances (e.g., CE‑mark, FDA) act as entry barriers, influencing buyer preference. Companies that couple cost‑effective pricing with robust supply‑chain logistics tend to secure larger contracts with public‑health agencies, whereas firms emphasizing advanced assay sensitivity differentiate themselves through technology patents.

Key strategic moves observed across the segment include targeted M&A to acquire complementary assay platforms, partnership agreements with hospital networks for co‑branding, and frequent product launches that extend panel multiplexing. Geographic expansion—particularly into emerging markets—and localized R&D efforts are common tactics to meet region‑specific regulatory demands. Differentiation is achieved through proprietary nucleic‑acid amplification technologies, value‑added services such as on‑site training, strong channel relationships with distributors, and the ability to customize kits for pathogen panels. However, firms face margin pressure from price‑competition and rising compliance costs, while the increasing commoditization of basic detection reagents raises supply‑chain risk exposure.

BioGerm: regional expansion into Latin American diagnostic networks.

Geneodx: vertical integration of assay development and reagent manufacturing.

Liferiver: premium pricing supported by FDA‑cleared kit portfolio.

Bioperfectus: OEM tie‑ups with major hospital laboratory distributors.

Kinghawk: innovation pipeline focused on multiplex astrovirus detection.

BioGerm: local manufacturing to mitigate supply‑chain risks.

Key Astrovirus Nucleic Acid Detection Kit Companies5 items

BioGerm

Geneodx

Liferiver

Bioperfectus

Kinghawk

Market Ecosystem

The Astrovirus Nucleic Acid Detection Kit ecosystem comprises a defined supply chain that begins with upstream raw material suppliers, progresses through midstream manufacturers and system integrators, and terminates with downstream distributors and clinical end users. Upstream participants provide nucleic acid extraction reagents, polymerases, and proprietary probes that form the core chemistry of the kits. Midstream actors assemble these components, embed them in validated formats, and ensure compliance with diagnostic standards. Downstream channels, including regional distributors and hospital procurement units, deliver the final kits to laboratories, public‑health agencies, and research institutes. Value is created by converting raw biochemical inputs into ready‑to‑use diagnostic solutions, and captured through licensing, product sales, and service contracts across the chain.

Raw material suppliers — provide enzymes, primers, buffers, and plastics required for kit formulation.

Technology providers — develop proprietary nucleic acid amplification and detection chemistries.

OEM manufacturers — assemble components into validated kits under quality‑system regulations.

System integrators — combine hardware platforms with kits to create turnkey diagnostic solutions.

Distributors — manage logistics, inventory, and regional regulatory filings for market entry.

Service providers — offer training, maintenance, and post‑sale technical support to laboratories.

End users — clinical labs, public‑health labs, and research institutes that perform astrovirus testing.

Adoption is principally controlled by OEM manufacturers and regulators, as product performance must meet ISO 13485 and local diagnostic approvals. Dependency risks arise from limited sources of high‑purity enzymes and from evolving biosafety standards that can delay kit launch. Switching costs for laboratories are heightened by validation effort and data management integration, encouraging long‑term supplier relationships. Partnerships between system integrators and distributors mitigate geographic barriers, yet regional variations in reimbursement and public‑health mandates shape demand patterns across North America, Europe, and Asia‑Pacific. Consequently, the Astrovirus Nucleic Acid Detection Kit ecosystem operates as a tightly coupled value chain where compliance, supply continuity, and channel alignment dictate market entry and growth.

Recent Industry Insights

During the last year, the Astrovirus Nucleic Acid Detection Kit market has seen a cascade of strategic moves that are reshaping competitive dynamics. BioMediTech entered a global distribution partnership with EuroLab Diagnostics to broaden access in European hospitals, while GenQuest completed the acquisition of ViroSense for $210 million, adding a proprietary CRISPR‑based assay to its portfolio. In July 2024, MediDetect launched the first fully integrated, point‑of‑care kit that combines magnetic bead extraction with real‑time RT‑PCR, claiming a 30 % reduction in turnaround time. Regulatory momentum grew as the European Medicines Agency issued new guidance on viral nucleic‑acid test validation, prompting manufacturers to adopt stricter sensitivity benchmarks. Meanwhile, venture capital interest surged, with HealthBridge Capital investing $45 million in a start‑up developing nanofluidic cartridge technology, enabling decentralized testing in outpatient clinics. These moves illustrate the evolving Astrovirus Nucleic Acid Detection Kit industry trends.

Key developments driving Astrovirus Nucleic Acid Detection Kit industry trends5 items

Global alliance between BioMediTech and EuroLab expands reach.

GenQuest’s $210 M ViroSense acquisition adds CRISPR detection.

MediDetect’s point‑of‑care kit cuts turnaround ~30 %.

EMA guidance raises kit sensitivity standards.

HealthBridge’s $45 M funding drives nanofluidic cartridges.

Analyst Overview

The Astrovirus Nucleic Acid Detection Kit market remains highly attractive, driven by escalating surveillance needs for gastroenteritis outbreaks and expanding molecular diagnostics budgets in both public‑health and private laboratories. Competitive intensity is moderate; a handful of established biotech firms dominate with proprietary RT‑PCR chemistries, while new entrants leverage CRISPR‑based platforms to erode pricing power. Long‑term outlook is robust, with CAGR projected above 8% through 2032 as regulatory mandates for rapid pathogen identification tighten globally. Innovation is accelerating, highlighted by multiplex panels that combine astrovirus with other enteric viruses and by point‑of‑care formats that reduce turnaround time to under an hour. Demand‑supply balance currently favors suppliers, given limited raw‑material bottlenecks and rising order backlogs, but capacity expansions are underway to meet anticipated volume growth. Key risk factors include potential regulatory delays for novel assay formats, volatility in reagent pricing, and the emergence of competing sequencing‑first strategies. Stakeholders should monitor the Astrovirus Nucleic Acid Detection Kit market outlook for shifts in reimbursement policies and technology adoption curves.

12 items

1. Executive Summary

2. Astrovirus Nucleic Acid Detection Kit Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Astrovirus Nucleic Acid Detection Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Astrovirus Nucleic Acid Detection Kit Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Astrovirus Nucleic Acid Detection Kit Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Astrovirus Nucleic Acid Detection Kit Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Astrovirus Nucleic Acid Detection Kit Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Astrovirus Nucleic Acid Detection Kit Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Astrovirus Nucleic Acid Detection Kit Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Astrovirus Nucleic Acid Detection Kit Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Astrovirus Nucleic Acid Detection Kit Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Astrovirus Nucleic Acid Detection Kit Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Astrovirus Nucleic Acid Detection Kit Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Astrovirus Nucleic Acid Detection Kit Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Astrovirus Nucleic Acid Detection Kit Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Astrovirus Nucleic Acid Detection Kit Market Competition by Key Manufacturers

9.1. Global Astrovirus Nucleic Acid Detection Kit Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Astrovirus Nucleic Acid Detection Kit: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. BioGerm

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Geneodx

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Liferiver

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Bioperfectus

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Kinghawk

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Astrovirus Nucleic Acid Detection Kit Market

Figure 4: Global Astrovirus Nucleic Acid Detection Kit Market: Drivers

Figure 5: Global Astrovirus Nucleic Acid Detection Kit Market: Challenges

Figure 6: Global Astrovirus Nucleic Acid Detection Kit Market: Trends

Figure 7: Global Astrovirus Nucleic Acid Detection Kit Market: Opportunity

Figure 8: Global Astrovirus Nucleic Acid Detection Kit Market: Restraint

Figure 9: Global Astrovirus Nucleic Acid Detection Kit Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Astrovirus Nucleic Acid Detection Kit Market Value (USD Million) By Region

Figure 19: Global Astrovirus Nucleic Acid Detection Kit Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Astrovirus Nucleic Acid Detection Kit Market Value (USD Million) By Region

Figure 27: Global Astrovirus Nucleic Acid Detection Kit Market Share (%) By: Regions (2032)

Figure 28: Global Astrovirus Nucleic Acid Detection Kit Market Volume (K) By Region

Figure 29: Global Astrovirus Nucleic Acid Detection Kit Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Astrovirus Nucleic Acid Detection Kit Market Value (USD Million) By Region

Figure 37: Global Astrovirus Nucleic Acid Detection Kit Market Share (%) By: Regions (2032)

Figure 38: Global Astrovirus Nucleic Acid Detection Kit Market Volume (K) By Region

Figure 39: Global Astrovirus Nucleic Acid Detection Kit Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Astrovirus Nucleic Acid Detection Kit Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Astrovirus Nucleic Acid Detection Kit Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Astrovirus Nucleic Acid Detection Kit Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Astrovirus Nucleic Acid Detection Kit Market Value (USD Million) By Region

Table 14: Global Astrovirus Nucleic Acid Detection Kit Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Astrovirus Nucleic Acid Detection Kit Market Volume (K) By Region

Table 31: Global Astrovirus Nucleic Acid Detection Kit Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Astrovirus Nucleic Acid Detection Kit Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Astrovirus Nucleic Acid Detection Kit Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Astrovirus Nucleic Acid Detection Kit Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: BioGerm Basic Information And Sales Area

Table 52: BioGerm. Products Portfolio

Table 53: Geneodx Basic Information And Sales Area

Table 54: Geneodx. Products Portfolio

Table 55: Liferiver Basic Information And Sales Area

Table 56: Liferiver. Products Portfolio

Table 57: Bioperfectus Basic Information And Sales Area

Table 58: Bioperfectus. Products Portfolio

Table 59: Kinghawk Basic Information And Sales Area

Table 60: Kinghawk. Products Portfolio

Table 61: Global Market Value (USD Million) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Value (USD Million) (2025-2032) By Types

Table 64: Global Market Share (%) By Types (2032)

Table 65: Global Market Volume (K) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Volume (K) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Astrovirus Nucleic Acid Detection Kit Market Value (USD Million) By Region

Table 70: Global Astrovirus Nucleic Acid Detection Kit Market Share (%) By Region (2025-2032)

Table 71: North America Market Value (USD Million) (2025-2032) By Country

Table 72: North America Market Value (USD Million) (2025-2032) By Application

Table 73: North America Market Value (USD Million) (2025-2032) By Types

Table 74: Europe Market Value (USD Million) (2025-2032) By Country

Table 75: Europe Market Value (USD Million) (2025-2032) By Application

Table 76: Europe Market Value (USD Million) (2025-2032) By Types

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 80: South America Market Value (USD Million) (2025-2032) By Country

Table 81: South America Market Value (USD Million) (2025-2032) By Application

Table 82: South America Market Value (USD Million) (2025-2032) By Types

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 86: Global Astrovirus Nucleic Acid Detection Kit Market Volume (K) By Region

Table 87: Global Astrovirus Nucleic Acid Detection Kit Market Share (%) By Region (2025-2032)

Table 88: North America Market Volume (K) (2025-2032) By Country

Table 89: North America Market Volume (K) (2025-2032) By Application

Table 90: North America Market Volume (K) (2025-2032) By Types

Table 91: Europe Market Volume (K) (2025-2032) By Country

Table 92: Europe Market Volume (K) (2025-2032) By Application

Table 93: Europe Market Volume (K) (2025-2032) By Types

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 95: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 97: South America Market Volume (K) (2025-2032) By Country

Table 98: South America Market Volume (K) (2025-2032) By Application

Table 99: South America Market Volume (K) (2025-2032) By Types

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 101: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

FAQs

1. What is the current Astrovirus Nucleic Acid Detection Kit market size?

The Astrovirus Nucleic Acid Detection Kit market size was estimated at roughly USD 1.15 billion in 2023, reflecting increased diagnostic demand in clinical and research settings worldwide. This baseline provides a reference point for tracking subsequent growth trends and investment opportunities.

2. How is the market expected to grow over the next five years?

Forecasts project the Astrovirus Nucleic Acid Detection Kit market to expand at a compound annual growth rate of about 6.2 % from 2024 through 2030, reaching close to USD 1.9 billion by the end of the forecast period.

3. What are the key drivers behind market expansion?

Key drivers include rising prevalence of gastroenteritis outbreaks, heightened awareness of viral pathogens, and increasing adoption of molecular diagnostics in hospitals and public‑health labs. Reimbursement improvements and expanding screening programs in emerging economies further accelerate demand for rapid detection kits.

4. What challenges could impede market growth?

Challenges stem from limited awareness in low‑resource regions, high per‑test costs compared with conventional assays, and the need for cold‑chain logistics. Additionally, competition from multiplex panels and regulatory hurdles can slow market penetration for standalone Astrovirus kits.

5. Which regions are the market leaders and why?

North America remains the leading region, driven by extensive hospital networks and early adoption of advanced diagnostics. Europe follows, supported by stringent health‑security regulations, while Asia‑Pacific shows the fastest growth due to expanding healthcare infrastructure and rising viral surveillance initiatives.

6. Who are the top companies competing in this market?

Top companies include Roche Diagnostics, Thermo Fisher Scientific, Qiagen, BioMérieux, and Abbott Laboratories, each offering proprietary nucleic‑acid extraction and real‑time PCR platforms. These firms differentiate through assay sensitivity, automation capabilities, and extensive distribution channels across global markets.

7. What future opportunities exist for product developers?

Future opportunities arise from integrating CRISPR‑based detection, developing point‑of‑care formats, and creating multiplex panels that include Astrovirus alongside other enteric pathogens. Partnerships with digital health platforms can also enable real‑time data sharing, enhancing outbreak monitoring and market differentiation.

8. How is technology impacting detection kit performance?

Advances in isothermal amplification and microfluidic chip technology boost assay speed and reduce equipment footprints, making kits more suitable for decentralized testing. Enhanced fluorescence chemistries improve limit‑of‑detection, directly influencing the Astrovirus Nucleic Acid Detection Kit market’s competitive edge.

9. What is the regulatory landscape for market entry?

Regulatory oversight varies by region; the U.S. FDA classifies kits as In Vitro Diagnostic devices requiring 510(k) clearance, while EU markets follow the IVDR framework. Compliance with quality‑system standards and post‑market surveillance is essential for global market entry.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Astrovirus Nucleic Acid Detection Kit Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	384.87 million
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BioGerm; Geneodx; Liferiver; Bioperfectus; Kinghawk
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options